Past mammograms are a valuable tool for benchmarking for change, but radiologists should keep in mind the diagnostic risks with respect to screenings where change is and isn’t observed.
Past mammograms are a valuable tool for benchmarking for change, but radiologists should keep in mind the diagnostic risks with respect to screenings where change is and isn’t observed.
That’s the conclusion of a new study considering more than a million screening mammograms, published online on Oct. 26 in the journal Radiology.
A team led by Bonnie C. Yankaskas, PhD, of the University of North Carolina School of Medicine, looked at 1,157,980 screening mammograms from 435,183 women ages 40 and up, taken from 1994 and 2008. The scans came from community practices in a wide variety of settings and among a diverse population of women and radiologists. Radiologists recorded the presence of comparison mammograms and whether there had been a visible change between the old and new mammograms. The team followed women for a year to monitor for cancer.
Yankaskas and colleagues measured performance of screening with and without comparison mammograms. When there was a comparison mammogram, the team assessed performance based on whether the comparison mammogram showed changes or not.
In screenings with comparison mammograms, the team found 3.7 cancers per 1,000 women, versus 7.1 per 1,000 in screenings without comparison mammograms. Why? The 6.9 percent of women in the study without comparison mammograms tended to be younger - and doing their first mammograms - which led to a higher detection rate, the authors said.
Comparison mammograms were available in 93 percent of examinations. For screening with comparison mammograms versus screening without comparison mammograms,
• Recall rate was 6.9 percent versus 14.9 percent;
• Sensitivity was 78.9 percent versus 87.4 percent; and
• Specificity was 93.5 percent versus 85.7 percent.
For screening with comparison mammograms that showed a change versus screening with comparison mammograms showing no change, the numbers were different:
• Recall rate was 41.4 percent versus 2 percent
• Sensitivity was 96.6 percent versus 43.5 percent; and
• Specificity was 60.4 percent versus 98.1 percent.
For this cohort, the cancer detection rate per 1,000 women was 25.4 in those with comparison mammograms showing change; in those showing no change, it was 0.8 percent. The cancers detected in both cases were ductal carcinoma in situ (roughly 20 percent of cases) and invasive carcinoma (roughly 80 percent of cases).
The authors concluded that using comparison mammograms is helpful, but conclusions should be assessed in terms of whether change is noted. When change is obvious, the false positive rate is high, and demands attention to those recommended for further work-up to reduce the high rate of false-positive findings. The reverse is true when no change is noted, which wins high specificity at the expense of low sensitivity. A large proportion of cancers are missed in this subgroup.
FDA Clears Enhanced MRI-Guided Laser Ablation System
June 5th 2025An alternative to an open neurosurgical approach, the Visualase V2 MRI-Guided Laser Ablation System reportedly utilizes laser interstitial thermal therapy (LITT) for targeted soft tissue ablation in patients with brain tumors and focal epilepsy.
Can Abbreviated MRI Have an Impact in Differentiating Intraductal Papilloma and Ductal Secretion?
June 3rd 2025For patients with inconclusive ultrasound results, abbreviated breast MRI offers comparable detection of intraductal papilloma as a full breast MRI protocol at significantly reduced times for scan acquisition and interpretation, according to a new study.
Can AI Assessment of PET Imaging Predict Treatment Outcomes for Patients with Lymphoma?
June 2nd 2025The use of adjunctive AI software with pre-treatment PET imaging demonstrated over a fourfold higher likelihood of predicting progression-free survival (PFS) in patients being treated for lymphoma, according to a new meta-analysis.